A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Sponsor: CStone Pharmaceuticals
A PHASE2 clinical study on Hodgkin Lymphoma, this trial is completed. The trial is conducted by CStone Pharmaceuticals and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Mar 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jan 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Aug 2018 — Jan 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CStone Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .